Biotechnology
The "Jiangsu-Germany Dialogue 2023" Held in Changzhou
CHANGZHOU, China, Sept. 15, 2023 /PRNewswire/ -- On September 12, the "Jiangsu-Germany Dialogue 2023" was held inChangzhou. This marks the third year of the event being hosted inChangzhou. The conference, themed "New Energy, New Opportunities", aims to further promote cooperation betweenChina and...
2023-09-15 16:38
1992
Cure Genetics and Frametact Reach a $60 Million Collaboration and Licensing Agreement for the Development of Gene Therapy for Familial Neurological Diseases
SUZHOU, China and HONG KONG, Sept. 14, 2023 /PRNewswire/ -- Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement. The partnership ...
2023-09-14 23:00
1919
Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphom...
2023-09-14 17:07
1555
Asieris' New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its oral drug APL-1401 for the tr...
2023-09-14 16:54
1538
Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene
CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of integrated antibody discovery and development solutions from "Idea to IND" (I to I™), announced an agreeme...
2023-09-14 16:00
1483
Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the clinical trial of oral APL-12...
2023-09-13 19:09
1517
Singleron launches AccuraCode® TCR library construction kit, enhancing efficiency and cost-effectiveness of high-throughput T-cell receptor profiling
COLOGNE, Germany, Sept. 13, 2023 /PRNewswire/ -- Singleron has announced the launch of its AccuraCode® TCR library construction kit for high-throughput T-cell receptor (TCR) profiling. It enables simultaneous analysis of hundreds of samples for T cell clonotypes, gene usage, V(D)J recombination p...
2023-09-13 17:51
1406
J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI
SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' was presented at the 2023 IASLC World Conference on Lung Cancer held inSingapore from 9th to 12th September, during the official session...
2023-09-13 15:58
1684
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD20...
2023-09-13 14:24
1481
Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7
- CBL-0201DD Phase 2 study met the primary and all secondary endpoints. - 64.5% of painful lipomas showed complete clearance or dimensions reduction of more than 50% after CBL-514 treatments. - 54.8% of painful lipomas showed complete clearance or dimension reduction of more th...
2023-09-13 13:42
1375
GemPharmatech's Board Appoints Brandy Wilkinson, Ph.D. as its New Chief Executive Officer of GemPharmatech LLC.
SAN DIEGO, Sept. 12, 2023 /PRNewswire/ -- GemPharmatech LLC., a leading
contract research organization, announced today that its Board of Directors has
appointed Dr.Brandy Wilkinson as the Chief Executive Officer of its subsidiary
inthe United States, effective September 12, 2023.
2023-09-13 00:00
1671
Standigm's "Green Ribbon Campaign" to support Mitochondria Disease Awareness Week
SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- On September 5th, 2023 Standigm, a company using artificial intelligence (AI) technology for drug discovery and development launched, the "Green Ribbon Campaign," event to support the upcoming Mitochondrial Disease Awareness Week scheduled for Se...
2023-09-12 21:00
1447
Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA
* HANSIZHUANG's coverage footprint includes 22 emerging market countries acrossSoutheast Asia and MENA – * KGbio to develop and commercialise HANSIZHUANG in 12 MENA countries; Henlius to receiveUS$7 million upfront payment plus royalties and up to US$8 million in regulatory milestone payments...
2023-09-12 19:24
1473
Mabwell and WuXi XDC Sign Long-Term ADC Strategic Collaboration to Accelerate Global Layout of Innovative Biologics
SHANGHAI, Sept. 8, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, and WuXi XDC, a leading global CRDMO, joint announced that they have signed a LOI for long-term strategic collaboration on Mabwell's multiple ADC projects. Mabwell has...
2023-09-08 15:30
1624
World Orphan Drug Alliance Welcomes Specialised Therapeutics
* SEA's largest independent specialty pharma company Specialised Therapeutics (ST) has joined global pharma consortium committed to collaborating to provide new specialist medicines for rare diseases. * ST to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA). * Wor...
2023-09-08 04:00
1728
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 6, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment o...
2023-09-06 20:00
1360
Gloria Biosciences Announces Zimberelimab Approved in China for the Treatment of Recurrent or Metastatic Cervical Cancer
* The first and only anti-PD-1 antibody approved for treating cervical cancer inChina * ORR of 27.8%, mPFS of 3.7m, and mOS of 16.8m achieved as monotherapy with best-in-class potential * A Phase 3 trial (VICT-004) of zimberelimab in combination with platinum-based chemotherapy +/- bevacizu...
2023-09-06 19:00
1420
CANbridge to Participate in Two Investor Conferences in September
BEIJING and BURLINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, today a...
2023-09-06 16:06
1641
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
Alteogen expects Tergase® will replace commercially available animal-derived hyaluronidase products and their significant disadvantages. Compared with other commercially available hyaluronidase products, Tergase® showed no incidence of anti-drug antibodies (ADA). The occurrence of ADA is known ...
2023-09-05 20:00
1297
David Topper Joined Inmagene as CFO
SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, today announced the appointment ofDavid Topper as Chief Financial Officer (C...
2023-09-05 20:00
1616
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8005
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7400